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Abstract
Treatment of human cells with Type 1 interferons restricts HIV replication. Here we report that the tripartite motif protein
TRIM22 is a key mediator. We used transcriptional profiling to identify cellular genes that were induced by interferon
treatment and identified TRIM22 as one of the most strongly up-regulated genes. We confirmed, as in previous studies, that
TRIM22 over-expression inhibited HIV replication. To assess the role of TRIM22 expressed under natural inducing conditions,
we compared the effects of interferon in cells depleted for TRIM22 using RNAi and found that HIV particle release was
significantly increased in the knockdown, implying that TRIM22 acts as a natural antiviral effector. Further studies showed
that TRIM22 inhibited budding of virus-like particles containing Gag only, indicating that Gag was the target of TRIM22.
TRIM22 did not block the release of MLV or EIAV Gag particles. Inhibition was associated with diffuse cytoplasmic staining of
HIV Gag rather than accumulation at the plasma membrane, suggesting TRIM22 disrupts proper trafficking. Mutational
analyses of TRIM22 showed that the catalytic amino acids Cys15 and Cys18 of the RING domain are required for TRIM22
antiviral activity. These data disclose a pathway by which Type 1 interferons obstruct HIV replication.
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Introduction
The interferon system is a well studied branch of the innate
immune system active against viruses. Infection of vertebrate cells
by many viruses provokes synthesis and secretion of interferons
(IFNs), which mediate induction of a cellular antiviral state that
obstructs further viral spread. Type I IFNs (a and b) are produced
by many cell types, while Type II IFN (gamma) is produced by
immune cells. IFN-induced signaling pathways begin with IFN
binding to IFN receptors at the cell surface. This results in signal
transduction via the Jak/Stat pathway, which leads to activation of
interferon-responsive genes and synthesis of effector proteins,
including PKR, RNAseL, Mx, and many others (reviewed in
[1,2,3,4]).
For HIV, previous studies have implicated IFNs in blocking
both early and late stages of the HIV-1 lifecycle [5,6,7,8,9,10]. In
many cell types, the inhibition of later steps in the life cycle
following integration seems to be most potent (reviewed in [2]).
Although the effector mechanisms acting late have not been fully
clarified, one report suggested that the IFN-inducible protein
ISG15 interfered with the endosomal trafficking pathway used by
HIV-1 to exit 293T cells by blocking the interaction of TSG101
with HIV-1 Gag [11].
Many tripartite motif (TRIM) proteins may function in innate
immunity to restrict viral replication. TRIM5a from rhesus
macaque (RhTRIM5a) blocks early replication steps of HIV-1
and other retroviruses (reviewed in [12]); in addition, one group
has proposed that RhTRIM5a acts late during HIV replication as
well [13]. The early target of RhTRIM5a is the capsid (CA)
protein, which forms the protein shell of the viral core. Anti-HIV-1
activity has also been reported for other TRIM family members.
TRIM1 has been shown to target the CA protein at an early stage
pre-reverse transcription, TRIM22 has been suggested to affect
HIV transcription and TRIM19 and TRIM32 have been
suggested to affect trafficking of viral proteins (reviewed in [14]).
Recently, TRIM28 was shown to repress transcription from a
retroviral promoter by binding to proviral DNA [15].
TRIM proteins contain a highly conserved RBCC motif
comprised of a RING domain, one or two B-box domains, and
a predicted coiled-coil region (reviewed in [14]). The RING
domain contains a specialized zinc finger [16] and has been shown
to possess E3 ubiquitin ligase activity [17,18,19,20,21,22]. Little is
known about the B-box domain, which is unique to TRIM
proteins. The coiled-coil domain is believed to promote protein
oligomerization [23]. Several TRIM proteins also contain a C-
terminal SPRY domain that is proposed to be involved in protein-
protein interactions and RNA binding [24,25].
Many TRIM family members are inducible by IFNs, providing
candidate mediators of IFN inhibition. In an effort to identify
TRIM proteins mediating anti-retroviral activity, we carried out
transcriptional profiling of IFN-treated human osteosarcoma
(HOS) cells and found that TRIM22 was the most up-regulated
TRIM queried on the microarray used. HOS-CD4/CXCR4 cells
were studied because they support robust HIV replication and
show a strong antiviral response to IFNb. Human TRIM22 (also
known as Staf-50) was previously identified from a search for IFN-
PLoS Pathogens | www.plospathogens.org 1 2008 | Volume 4 | Issue 2 | e1000007regulated genes in Daudi cells. Over-expression of TRIM22 was
reported to repress transcription from the HIV-1 LTR in a
plasmid reporter system in COS-1 cells [26]. In a later study by
another group, over-expression of TRIM22 was reported to
inhibit HIV-1 replication in human macrophages and 293T cells
and postulated to act by repressing transcription from the HIV-1
LTR [27]. TRIM22 has also been implicated in normal
haematopoietic differentiation [28,29] and in diseases such as
systemic lupus erythematosus [30] and Wilms tumor [31]. The
expression of TRIM22 is altered in response to a variety of stimuli
in addition to IFN including T-cell co-stimulation by CD2 and
CD28 [32], viral antigens or infection [27,33,34,35] and
inflammatory cytokines [28].
Here we investigate the mechanism by which TRIM22 inhibits
HIV infection. We mapped the primary block to late stages of
assembly and release in the viral life cycle using over-expression
studies. Short hairpin RNA against TRIM22 substantially
reversed the inhibition of late steps induced by IFN treatment,
implicating TRIM22 as a functional effector when expressed at
biological levels. TRIM22 blocked the release of HIV-1 Gag-only
particles, and the release of HIV particles was dependent on the
RING domain of TRIM22. These findings clarify an IFN-
inducible effector arm that disrupts the late stages of HIV
infection.
Results
TRIM22 restricts HIV-1 replication in HOS-CD4/CXCR4
cells
Human osteosarcoma cells modified to express CD4 and
CXCR4 (HOS-CD4/CXCR4) support robust HIV-1 replication,
which is potently restricted by pre-treatment with IFNb.W e
wished to identify restriction factors induced by IFNb, and so
carried out transcriptional profiling of HOS-CD4/CXCR4 cells
before and after IFNb treatment. As expected, a large number of
genes were induced (52 total with a false discovery rate of 7%;
Table S1), including the well-known antiviral genes OAS1 (,235-
fold), MX1/2 (,24-fold), ISG20 (,37-fold), ISGF3G (,12-fold),
IRF7 (,13-fold) and TRIM19zeta (,18-fold).
We focused our study on TRIM22, which was induced at least
86-fold after IFNb-treatment. Other TRIM genes that were
notably up-regulated included TRIM19 variants (2.8 to 18-fold),
TRIM21 (2.6-fold), TRIM34 variant 1 (2.4-fold) and TRIM5delta
(2.4-fold), consistent with previous studies [26,36,37,38,39]. Gene
chip data on TRIM22 induction was confirmed using Northern
blot analysis (Figure 1A). These results support previous studies of
other cell types, although we observed a higher level of IFNb-
induced TRIM22 expression than previously reported [4,27].
To analyze TRIM22 inhibition of HIV-1 replication, we
generated HOS-CD4/CXCR4 cells that stably express hemag-
glutinin (HA)-tagged TRIM22 protein (Figure 1B). There was no
significant difference between the doubling times of the empty
vector control cells (24.4+/22.4 hours) and the cells expressing
TRIM22 (25.5+/21.8 hours) (P=0.7, Mann-Whitney Test),
indicating TRIM22 expression was not detectably toxic. Cells
stably expressing TRIM22 were then infected with increasing
amounts of replication-competent HIV-1. Virus released into the
Figure 1. Expression of TRIM22 in HOS-CD4/CXCR4 cells blocks
late steps in HIV replication. A) Induction of TRIM22 RNA levels by
IFNb treatment of HOS-CD4/CXCR4 cells. Cells were pre-treated with
1000 units/ml of IFNb, RNA isolated and subjected to Northern blot
analysis. The TRIM22 39UTR was labeled and used as a probe. B) Stable
expression of HA-tagged TRIM22 in HOS-CD4/CXCR4 cells verified by
Western blotting. C) Inhibition of HIV replication in cells stably
expressing TRIM22. Cells were infected with different concentrations
of replication-competent HIV-1 R9. After 72 hours, virus released into
the supernatant was pelleted and assayed for p24CA levels by Western
blot. The numbers below the Western blots correspond to the amounts
of virus added to each well, quantified according to the amount of
reverse transcriptase activity. D) TRIM22 does not inhibit early HIV
replication steps, subsequent to entry. The TRIM22 expressing cells
were infected with different amounts of HIV-1/VSVG pseudotyped virus
and analyzed by FACS for GFP expression. Data obtained from a second
independently generated cell line expressing TRIM22 (#2) are also
shown. Data shown are representative of two independent infections
for each performed in quadruplicate (+/2StdDev).
doi:10.1371/journal.ppat.1000007.g001
Author Summary
Interferons are produced by cells in response to challenge
by foreign pathogens such as viruses. The molecular
mechanisms by which Type I interferons (e.g., IFNb) inhibit
the replication of HIV-1 are not fully clarified. We identified
a gene called TRIM22 that belongs to the tripartite motif
(TRIM) family that was strongly induced by IFNb. Using
RNA interference to reduce the expression of TRIM22, we
showed that TRIM22 is a key mediator of the IFNb
response when expressed at natural levels. We demon-
strate that TRIM22 blocks the intracellular trafficking of the
viral structural protein Gag to the surface of the cell, and
that the antiviral activity of TRIM22 is dependent on two
cysteine residues (Cys15 and Cys18) that are critical for the
E3 ligase activity of RING-containing proteins. This report
describes a mechanism by which Type I interferons block
HIV-1 replication.
TRIM22 Inhibits HIV Particle Production
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p24CA antibodies in a Western blot (Figure 1C). Cells expressing
TRIM22 released substantially less virus than the control cells.
Similar results were obtained using another HIV-1 clone LAI (data
not shown). These findings parallel a previous report [27].
TRIM22 blocks late events of the HIV-1 lifecycle
We next analyzed the step in the HIV-life cycle affected by
over-expression of TRIM22. To test for inhibition of early steps
(entry through integration), we infected cells with HIV-1
pseudotyped with the VSV-G envelope and transducing GFP.
We infected two isolates of the HOS-CD4/CXCR4 cell lines
expressing TRIM22 and found no reduction in the fraction of cells
positive for GFP (Figure 1D), indicating that TRIM22 did not
strongly affect HIV/VSV-G early steps.
To test whether TRIM22 interferes with late events in the HIV
lifecycle, we co-transfected plasmids encoding TRIM22 and a
replication-competent HIV provirus. Forty-eight hours after
transfection, Western blots of cell lysates and extracellular
supernatants were probed with an antibody against the p24 capsid
component of the Gag polyprotein (Figure 2). Co-expression of
TRIM22 blocked the release of virions from HOS-CD4/CXCR4
cells, despite the production of substantial amounts of intracellular
Gag (Figure 2). Gag also failed to accumulate in the extracellular
supernatant in transfected U2OS, 143B and HeLa cells.
The nature of the blocks differed among the cell types studied.
After correcting with an internal transfection control (peGFP), Gag
proteins accumulated to a reduced extent in U2OS and 143B cells
in the presence of TRIM22, while Gag accumulated inside cells to
near wild-type levels in HOS-CD4/CXCR4 and HeLa cells but
were not released (Figure 2 and data not shown). In all cell types,
however, accumulation of extracellular Gag was abolished by co-
expression with TRIM22.
Knocking down TRIM22 using RNA interferences boosts
HIV particle production in the presence of IFNb
The above data and results in [27] indicated that ectopic
expression of TRIM22 can interfere with HIV replication, but
from over-expression data alone it is uncertain whether expression
at physiological levels would result in antiviral activity. For this
reason, we tested whether depleting TRIM22 using short hairpin
ribonucleic acid (shRNA) in the context of an interferon response
allowed increased production of extracellular HIV particles. HOS-
CD4/CXCR4 cells were transiently transfected for 24 hours with
either pLKO.1/TRIM22shRNA#1 or the empty vector control
(pLKO.1). In control cells, TRIM22 RNA accumulation increased
in the presence of increasing concentrations of IFNb. In the cells
expressing the TRIM22 shRNA, TRIM22 RNA levels were
significantly reduced (Figure 3A and B). As a control, expression of
the related TRIM34 gene was tested and found to be unaffected by
the TRIM22 shRNA (Figure 3A).
The knockdown cells and the control cells were then tested for
their ability to release HIV-1 virus after transfection with a
plasmid encoding replication-competent HIV-1 (pR9). Accumu-
lation of HIV Gag in cells and supernatants was monitored by
Western blot using p24CA antibodies (Figure 3C). In the absence
of IFNb, the control cells released virus into the supernatant. In
the presence of increasing concentrations of IFNb, cells displayed
a progressive reduction in the amount of virus released, reaching
undetectable levels at 1000 units/ml of IFNb. There was little
effect of IFNb on intracellular Gag expression levels, indicating
that IFNb acts at the level of virus assembly and/or release in
HOS-CD4/CXCR4.
Cells knocked down for TRIM22, when treated with IFN,
released substantially more virus into the cell supernatant than
control IFN-treated cells (Figure 3C, 500 and 1000 units/ml of
IFNb). Figure 3D compares the fold decrease in particle release
after treatment with 1000 units/ml of IFNb in cells transfected
with the empty vector control, an irrelevant target (eGFP) control
(pLKO.1/eGFPshRNA), a scrambled shRNA control ( pLKO.1/
scramshRNA) and two different TRIM22 shRNAs targeting a
different region of the TRIM22 39 UTR. Gag release was
inhibited by IFN more strongly in cells transfected with each of the
control shRNAs than in cells transfected with TRIM22 shRNA.
Over 14 control experiments, the fold-inhibition values for
1000 units/ml IFNb ranged from 3.0-fold to 7.4-fold. Over 8
experiments with two different TRIM22 shRNAs and 1000 u
Figure 2. TRIM22 inhibits accumulation of viral particles in cell
supernatants. HOS, U2OS, 143B and HeLa cells were studied (labeled
to the left of the gels). Cells were co-transfected with pR9 (encoding
full-length HIV-1) and pTRIM22 or the control empty expression vector
pcDNA3.1. After 48 hours, Western blots were performed on the
supernatants (left panels) and cell pellets (right panels) using p24CA
antibodies.
doi:10.1371/journal.ppat.1000007.g002
TRIM22 Inhibits HIV Particle Production
PLoS Pathogens | www.plospathogens.org 3 2008 | Volume 4 | Issue 2 | e1000007IFNb, inhibition ranged from 1.2-fold to 1.6-fold. The difference
between the means of the fold-inhibition values of TRIM22
shRNA (1.4-fold) and the pooled controls (4.5-fold) was highly
significant (P=0.0002 Mann-Whitney) (Figure 3E). These data
indicate that TRIM22 is an active antiviral effector in the context
of the normal response to IFNb.
TRIM22 inhibits budding of HIV-1 Gag-only particles
The HIV Gag polyprotein is transported to the plasma
membrane after translation where it assembles into particles and
buds from the cell surface. Gag protein alone is able to bud from
cells when expressed in the absence of the other HIV-1 proteins
(reviewed in [40]). We asked whether TRIM22 acted on the Gag
Figure 3. Knockdown of TRIM22 by RNA interference abrogates interferon-induced inhibition of HIV replication. A) HOS-CD4/CXCR4
cells were transfected with the empty vector control plasmid pLKO.1 or pLKO.1/TRIM22 shRNA#1 followed by treatment with 0, 50, 500 or 1000 units/
ml of IFNb (represented by triangles at the top of the Northern blots). Total RNA was extracted and subjected to Northern blot analysis to detect
TRIM22 RNA transcripts. TRIM34 (variant 3) RNA transcript levels were also detected for a comparison (middle row). Input RNA was normalized using
Northern blots probed with an actin fragment (bottom row). B) Quantitation of the Northern blots in A, indicating the fold induction of TRIM22 RNA
in response to the IFNb treatment. C) Cells were transfected with the empty vector pLKO.1 or pLKO.1/TRIM22shRNA#1 and treated with 1000 units/ml
of IFNb. Cells were then transfected with pR9 and Western blot analysis of HIV capsid antigen in cells and supernatants was analyzed using an anti-
p24 antibody. D) Cells were transfected with the control plasmids pLKO.1, pLKO.1/eGFPshRNA or pLKO.1/scrambledshRNA or TRIM22 shRNA plasmids
pLKO.1/TRIM22shRNA#1 and pLKO.1/TRIM22shRNA#2 and treated with 1000 units/ml of IFNb. Following transfection with pR9, HIV capsid antigen
released into the supernatant was detected by Western blot and quantified densitometrically. Data represents the averages (+/2StdDev) of at least 3
experiments performed in triplicate. E) A comparison of the average fold inhibition in particle release of the pooled control shRNAs and the pooled
TRIM22 shRNAs (+/2StdDev). *, P=0.0002 (Mann-Whitney).
doi:10.1371/journal.ppat.1000007.g003
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particles.
We co-transfected a codon-optimized HIV Gag expression
plasmid in the presence or absence of TRIM22 and measured the
accumulation of Gag proteins in the cells and in culture
supernatants by Western blot (Figure 4A). In the absence of
TRIM22, Gag protein was detected in the cell lysate and
efficiently released into the supernatant. In the presence of
TRIM22, Gag was readily detected in the cell lysate, but not the
supernatant. This effect parallels the effect of IFNb on Gag-only
particle release in HOS-CD4/CXCR4 cells (Figure 4B).
To assess the specificity of TRIM22, we assayed effects on
murine leukemia virus (MLV) and equine infectious anemia virus
(EIAV) Gag. Co-transfection of TRIM22 with either MLV Gag-
Pol or EIAV Gag-Pol failed to restrict the release of Gag-
containing particles into the supernatant, whereas TRIM22
restricted the release of HIV-1 Gag (Figure 4C). Together these
data indicate that TRIM22 acts selectively on HIV-1 Gag.
TRIM22 alters Gag trafficking to the plasma membrane
We next investigated whether TRIM22-mediated inhibition was
associated with altered Gag trafficking by monitoring the
subcellular localization of HIV Gag fused to GFP (pGag-GFP)
[41,42,43,44]. We transfected pGag-GFP in the presence or
absence of pTRIM22, then 3 hours later treated the cells with
cycloheximide for 3 hours. Forty-eight hours after release of the
cycloheximide block, the localization of the Gag-GFP protein was
visualized by fluorescence microscopy by taking optical slices
through the center of cells (Figure 5A). In the control cells, 65% of
GFP-positive cells had punctate fluorescence at or near the plasma
membrane and 35% of the cells showed diffuse cytoplasmic
fluorescence. In contrast, in cells expressing TRIM22, 12% of the
cells had punctate fluorescence at or near the plasma membrane
and 88% of the cells yielded diffuse cytoplasmic localization
without visible puncta (Figure 5B). The observed difference in
proportions was highly significant (P,0.0001, Chi-square test).
To test whether IFNb altered Gag localization, as with
TRIM22 expression alone, we compared the effects of pre-
treating cells with 1000 units/ml of IFNb followed by transfection
with GagGFP and microscopy. In the absence of IFNb, 64% of
GFP-positive cells had punctate fluorescence at or near the plasma
membrane and 36% of the cells showed diffuse cytoplasmic
fluorescence. In contrast, 22% of the IFNb-treated cells had
punctate fluorescence at or near the plasma membrane and 78%
of the cells yielded diffuse cytoplasmic localization without visible
puncta (Figures 5A and 5B). The difference in the number of cells
exhibiting punctate localization at the cell surface before and after
IFNb-treatment was highly significant (P,0.0001, Chi-Square)
and paralleled the result with the expression of TRIM22 alone.
To determine whether the diminished accumulation of Gag at
the plasma membrane is due to accelerated degradation of Gag,
we performed pulse-chase analysis on intracellular Gag levels in
HOS-CD4/CXCR4 cells (Figure 5C). The half life of Gag was
4.4 hours in cells transfected with the empty vector control
(pcDNA) and 4.5 hours when TRIM22 was co-transfected. In
addition, Western analysis also yielded similar levels of intracel-
lular Gag protein in the presence and absence of TRIM22 (data
not shown). These data indicate that inhibition of particle release
by TRIM22 is associated with diminished accumulation of Gag at
the plasma membrane and is not likely the result of increased
turnover of Gag in HOS-CD4/CXCR4 cells.
The myristoylation of Gag is an important requirement for
targeting Gag to the plasma membrane and for virus assembly and
release [45,46,47,48,49]. We asked whether the TRIM22-
mediated disruption of Gag trafficking is a result of a defect in
Gag myristoylation. We co-expressed Gag with or without
TRIM22 in the presence of
3H-myristic acid and immunoprecip-
itated Gag from the cellular extract with anti-p24CA. Gag
myristoylation was readily detected both in the absence and
presence of TRIM22, indicating that TRIM22 does not block the
myristoylation of Gag (Figure 5D). A fraction of the immunopre-
cipitated protein was subjected to Western blot analysis using anti-
p24CA, confirming the presence of comparable amounts of Gag
protein in both of the samples.
The E3 ligase catalytic site of TRIM22 is required for
antiviral activity
The modification of proteins by E3 ligases is known to be
associated with altered endocytic trafficking (reviewed in [50,51]).
Since TRIM22 alters Gag trafficking and the RING domain of
Figure 4. TRIM22 expression blocks release of HIV-1 Gag-only
particles. A) Cells were transfected with pGag and pTRIM22 or pcDNA.
Cells and Gag-only particles released into the supernatant were isolated
24 hours after transfection and analyzed by Western blotting using an
anti-p24CA or anti-actin antibody. B) Cells were pre-treated for 16 hours
with 1000 units/ml of IFNb followed by transfection with pGag. Cells
and Gag-only particles released into the supernatant were isolated after
24 hours and analyzed by Western blotting using an anti-p24CA
antibody. C) Cells were co-transfected with pR9 or a plasmid expressing
MLV GagPol (pMLV) or an EIAV packaging vector (pEIAV) with or
without TRIM22 for 24 hours. Cells and Gag-containing particles were
isolated and analyzed by Western blotting using an anti-capsid
antibody.
doi:10.1371/journal.ppat.1000007.g004
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ligase active site, present in the RING domain, is required for the
antiviral effects of TRIM22. We mutated two conserved cysteine
residues (C15A/C18A) in the RING domain that have been
shown to inactivate the ubiquitin ligase activity in other TRIMs
[17,52,53].
We found that cells co-transfected with pR9 and either the
empty vector control or the pTRIM22 C15A/C18A mutant did
not block the release of virus, though wildtype TRIM22 blocked
quite strongly (Figure 6). Gag accumulated inside cells to near
wild-type levels (Figure 6, second panel) and the expression levels
of wildtype TRIM22 and the C15A/C18A mutant were similar
(Figure 6, second panel). These data implicate the catalytic
cysteine residues at position 15 and 18 of the RING domain as
important for the observed antiviral effects of TRIM22.
We next asked whether we could detect an interaction between
TRIM22 and Pr55Gag. We immunoprecipitated a Gag-GFP
fusion protein expressed in the presence of FLAG-tagged TRIM22
with anti-GFP antibodies and then performed a Western blot with
anti-Flag antibodies and detected co-precipitation of FLAG-
TRIM22 (Figure 7). Reverse immunoprecipitation using anti-
FLAG pulled down Gag-GFP only when FLAG-TRIM22 was co-
expressed. Treatment of the samples with RNaseA prior to
immunoprecipitation did not interfere with the association of
TRIM22 with Gag, indicating that an RNA bridge did not
mediate the interaction. TRIM22 did not co-immunoprecipitate
Figure 5. TRIM22 alters the sub-cellular localization of Gag protein. A) Analysis of Gag localization by fluorescence microscopy. HOS-CD4/
CXCR4 cells were co-transfected with pTRIM22 and pGag/GFP for 3 hours, washed and incubated with 100 mM cycloheximide for 3 hours. IFNb pre-
treatment was done for 16 hours prior to transfection with pGag/GFP. Cells were washed and incubated in fresh media for a further 48 hours. Gag-
GFP localization was assessed using fluorescence microscopy. High magnification images of the white squares are shown to the right. B)
Quantifications of images as in A from three independent experiments. GFP-positive cells were classified as showing either punctate fluorescence at
the cell periphery or diffuse cytoplasmic fluorescence. The number of cells counted was: pcDNA, n=332; TRIM22, n=386; 2IFNb=497; +IFNb=398.
C) HOS-CD4/CXCR4 cells were co-transfected with pGag in the absence or presence of pTRIM22 and pulse-chase analysis of intracellular Gag protein
was done. D) Detection of
3H-myristic acid-labeled Gag. Cells were co-transfected with pGag in the absence or presence of pTRIM22 for 24 hours and
then labeled with
3H-myristic acid overnight. Gag was immunoprecipitated and resolved on a SDS-PAGE gel before exposure to film (‘‘Labeled Gag’’)
or Western blot analysis using anti-p24CA (‘‘Total Gag’’).
doi:10.1371/journal.ppat.1000007.g005
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binds specifically to HIV Gag.
Discussion
Here we present data that TRIM22 is an interferon inducible
effector that is responsible at least in part for the late IFNb block to
HIV-1 replication. We observed, as have others, that over-
expression of TRIM22 in cells obstructed HIV replication. We
show here that knockdown of TRIM22 in HOS-CD4/CXCR4
cells in the context of a natural IFN response abrogated the late
block to HIV replication, implicating TRIM22 as an antiviral
effector. TRIM22 expression was able to block release of HIV-1
Gag-only virus-like particles, but not MLV or EIAV Gag particles,
indicating that TRIM22 acts specifically on the HIV Gag protein.
In binding studies, TRIM22 associated with HIV-1 Gag but not
MLV or EIAV Gag. TRIM22 expression altered Gag localiza-
tion–cells containing Gag-GFP fusions showed punctate structures
at the plasma membrane, potential sites of virus assembly and
budding [41,54,55]. In contrast, Gag-GFP expressed in the
presence of TRIM22 alone or IFNb showed only diffuse staining.
TRIM22 with substitutions in the E3 catalytic residues were
unable to restrict HIV-1 release, indicating that inhibition was
dependent on the active site. Taken together, these data implicate
TRIM22 as an effector arm of the IFN-mediated antiviral state
that selectively disrupts Gag sorting and release.
Complications in studying mechanisms of the IFN response
arise from i) the pronounced cell type specificity of IFN action, ii)
differential effects of different doses, and iii) differences among the
effects of interferon types. Previous studies have reported that
Type I IFNs can block HIV gene expression, Gag sorting, and
Gag release [9,11,26,56,57,58,59,60,61,62]. Here we show, using
HOS-CD4/CXCR4 cells, that TRIM22 acts on HIV Gag,
allowing efficient Gag expression but blocking assembly and/or
release. Similar results were seen in HeLa cells. However, in
U2OS and 143B cells, TRIM22 expression resulted in reduced
accumulation of Gag in cells, indicating that TRIM22 inhibited
either Gag synthesis or increased Gag turnover. A previous study,
analyzing TRIM22 in COS cells, indicated that TRIM22
inhibited LTR-driven transcription. A similar mechanism may
operate in U2OS cells and 143B cells. Recently, rhesus TRIM5a
(but not its human ortholog) was shown to cause the rapid
degradation of Gag in 293T cells [63]. We found no evidence that
TRIM22 drastically altered the stability of Gag protein levels in
HOS-CD4/CXCR4 or HeLa cells, however it is possible that
altered Gag sorting results in faster degradation in U2OS and
143B cells than seen in HOS-CD4/CXCR4 and HeLa cells.
Against this background of cell type specific effects, comparisons
of our results to previous reports are quite tentative. In one study,
addition of 500 units/ml of IFNa to 293T cells was reported to
inhibit HIV particle release about two-fold, and an siRNA against
the interferon-induced ubiquitin-like molecule ISG15 blocked IFN
inhibition [64,65,66]. In HOS-CD4/CXCR4 cells treated with
IFNb at 1000 units/ml, the inhibition of particle release was
stronger (3.0-fold to 7.4-fold), but the shRNA against TRIM22 did
not completely reverse IFN inhibition. One possibility is that
TRIM22 and ISG15 both act in the same pathway. For example,
TRIM22 might act as an E3 ligase for ISG15. Further
experiments will be needed to assess the relationship of inhibition
by TRIM22 to that of ISG15.
Another recent report suggested that IFNa treatment caused
HIV-1 virions to become tethered to cell surfaces, resulting in
eventual re-uptake by endocytosis [67]. The viral Vpu protein was
reported to overcome this block in some cell types. It is possible
that the mis-sorting of Gag observed here in HOS-CD4/CXCR4
cells results from virions trafficking to the membrane followed by
re-uptake, though in HOS-CD4/CXCR4 cells there was no
evidence for Gag accumulating at membranes at early times as
might be expected from the re-uptake model. Also, in the HOS-
CD4/CXCR4 cell model, expression of Gag in the presence or
absence of Vpu did not noticeably affect particle accumulation in
the supernatant. It will be useful to identify the cell type or
experimental differences responsible for these divergent observa-
tions.
How human TRIM22 alters intracellular Gag trafficking in
HOS-CD4/CXCR4 cells is unknown but a fascinating problem
for further study. One candidate model would be that TRIM22
acts by interfering with Gag binding to membranes via the linked
myristate residue. Membrane binding of Gag has been reported to
be regulated by a multimerization-dependent myristoyl switch
[68,69,70,71]. We found that Gag was myristoylated normally in
the presence of TRIM22 (Figure 5C) but TRIM22 might affect
Gag multimerization and resulting exposure of the myristate
residue. We also found that that the E3 ligase activity of TRIM22
Figure 6. E3 ligase catalytic site is required for HIV particle
release. pR9 was transfected with or without pcDNA, pTRIM22 or
pT22-C15A/C18A for 24 hours. Western blots were performed on virus
released into the supernatants (top panel) using anti-p24CA and on the
cell pellets (lower panels) using anti-p24CA, anti-HA or anti-actin
respectively.
doi:10.1371/journal.ppat.1000007.g006
Figure 7. TRIM22 interacts with Gag. HOS-CD4/CXCR4 cells were
co-transfected with pGag-GFP and pFLAG-TRIM22 (or empty vector
control pFLAG) and immunoprecipitated with anti-GFP or anti-FLAG.
Precipitated Gag and TRIM22 were detected by Western blotting using
p24CA or FLAG antibodies.
doi:10.1371/journal.ppat.1000007.g007
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TRIM22 probably disrupts Gag trafficking by transferring
ubiquitin (or an ubiquitin-related moiety) to one or more targeted
proteins. Although TRIM22 interacts with Gag, we have yet to
detect a convincing effect of TRIM22 on the levels of Gag
ubiquitylation or a size-altering modification of Gag (data not
shown), raising the possibility that a cellular protein involved in
Gag trafficking is the target. Thus studies of TRIM22 link E3
ligases, IFN, and HIV late replication steps, providing a new
experimental route to investigating these issues.
Materials and Methods
Cell lines, plasmids and antibodies
293T, HOS-CD4/CXCR4, HeLa, 143B, and U2OS were
maintained in standard growth media (Dulbecco’s Modified
Eagle’s Medium (DMEM), supplemented with 10% heat-inacti-
vated Fetal Bovine Serum (FBS), 100 U/ml Penicillin and
100 mg/ml Streptomycin) at 37uC with 5% CO2. HOS-CD4/
CXCR4 cells stably expressing TRIM22 was generated by
transfecting the cells with pTRIM22 followed by selection with
2 mg/ml of Genetecin. pTRIM22 was generated by cloning the
TRIM22 coding region (GenBank Accession X82200) into
pcDNA3.1HA using MfeI and XhoI restriction sites to generate
pTRIM22. pFLAG/TRIM22 was generated by cloning the same
TRIM22 coding region into p3xFLAG-CMV-10 (Sigma) using
HindIII and XbaI restriction sites. pT22-C15A/C18A was
generated using the QuikChange Site Directed Mutagenesis kit
(Stratagene) according to manufacturer’s directions. pTRIM22
was used as the template and the oligos used were 59 gag aag gag
gtg acc gcc ccc atc gcc ctg gag ctc c 39 (forward) and 59 gga gct cca
ggg cga tgg ggg cgg tca cct cct tct c 39 (reverse). pGag/GFP was a
generous gift from M. Resh (Sloan-Kettering Institute). The
plasmids pLKO.1 (Cat. #RHS4078), pLKO.1/eGFPshRNA (Cat.
#RHS4459), pLKO.1/TRIM22shRNA#1 (Cat. #RHS3979-
9574742; GenBank Accession NM_006074, sequence: 59 cgg
agc act cat cta caa gtt ctc gag aac ttg tag atg agt gct ccg 39) and
pLKO.1/TRIM22shRNA#2 (Cat. #RHS3979-9574744; GenBank
Accession NM_006074, sequence: 59 gtc acc aaa cat tcc gca taa ctc
gag tta tgc gga atg ttt ggt gac 39) were obtained from Open
Biosystems. pLKO.1/scrambledshRNA (Addgene plasmid 1864;
sequence 59 cctaa ggtta agtcg ccctc gctct agcga gggcg actta acctt
agg 39) was obtained from [72] through Addgene. pEIAV
(‘‘pEV53B’’) was obtained from [73]. pMLV (‘‘pCgp’’) was
obtained from [74]. The plasmid encoding codon-optimized
Gag (p96ZM651gag-opt) (from Drs. Yingying Li, Feng Gao and
Beatrice H. Hahn [75]) and the HIV-1 p24 monoclonal antibody
(183-H12-5C) (from Dr. Bruce Chesebro and Kathy Wehrly
[76,77,78]) were obtained through the NIH AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID, NIH.
Poly/MonoUbiquitin (FK2, #PW8810) and PolyUbiquitin (FK1,
#PW8805) antibodies were obtained from Biomol International.
Unless otherwise stated, all plasmid transfections were performed
using Lipofectamine 2000 (Invitrogen). Co-transfections were
performed at a 1:10 ratio (pR9 or pGag or pGagGFP: pcDNA
or pTRIM22 or pT22-C15A/C18A respectively).
Microarray analysis
RNA was harvested from HOS-CD4/CXCR4 cells in log-
phase growth 24 hours after human interferon beta (PBL
Biomedical Laboratories Cat. #11420-1) treatment using a
Qiagen RNeasy Kit. Labeling of RNA was done using standard
techniques as described by Affymetrix (Santa Clara, CA). Two
independent RNA samples were hybridized with Affymetrix HG-
U133A chips in duplicate. Significance Analysis of Microarray
software using a cut-off difference of 2-fold and a false discovery
rate of 7% was used to analyze changes in gene activity after
human IFNb treatment via the permuted t test method [79].
Microarray data is available upon request.
Virus production and infections
HIV-1/VSV-G vector particles were generated by calcium
phosphate-mediated transfection of 293T cells with three plas-
mids: p156RRLsinPPTCMVGFPWPRE (encoding the HIV-1
vector segment) [80], pCMVdeltaR9 (the packaging construct),
and pMD.G (encoding the VSV-G envelope) [81]. Replication-
competent virus (R9 and LAI clones) was generated by calcium
phosphate-mediated transfection of 293T cells with pR9 or pLAI
plasmids. Virus was quantitated for reverse transcriptase activity
using standard protocols [82].
Prior to infection, virus aliquots were digested with DNaseI
(0.2 units/ml) for 1 hour at 37uC. Cells were infected with varying
amounts of virus for 3 hours at 37uC in a minimal volume of
media, after which the media containing virus was replaced with
fresh media and the cells were then incubated for the desired time.
Quantitation of virus and Gag particle release
Virus released into the supernatant was pelleted and lysed as
described in [82]. Briefly, 1ml viral supernatants were clarified by
centrifugation at 350 g for 10 mins at 4uC and passed through a
0.45 mm filter. Virus was precipitated overnight on wet ice at 4uC
using 0.56 volumes of PEG solution (30% PEG 8000, 0.4 M
NaCl). Precipitated virus was pelleted by centrifugation at 800 g
for 45 minutes at 4uC. Gag particles were prepared as previously
described [42,44]. Briefly, 800 ml of supernatant containing Gag
particles were pelleted by centrifugation at 20,000 g for 90 mins at
4uC over a 500 ml cushion of 20% sucrose.
PEG-precipitated virus and sucrose-purified Gag particle pellets
were lysed with 75 ml and 30 ml of lysis buffer respectively and
2 ml–5 ml of the lysed pellets was used for Western blotting. Lysis
buffer consisted of a fresh mix of Buffer A and Buffer B (2:1 ratio
respectively). Buffer A contained 12.5 ml of 1 M Tris (pH 7.8),
1.25 ml of 0.1 M EDTA (pH 8.0), 1.25 ml of 10% Triton X-100,
250 ml of Glycerol, 0.77 g of DTT and 3.72 g of KCl with the
volume brought up to 500 ml with ddH2O. Buffer B contained
45 ml of 10% Triton X-100 and 1.63 g KCl with the volume
brought up to 500 ml with ddH2O.
For analysis of cell lysates, cells were centrifuged at 350 g for
5 mins, washed twice with phosphate-buffered saline (PBS) and
lysed with 50 ml of RIPA buffer (50 mM Tris-HCl (pH 7.4),
150 mM NaCl, 1 mM EDTA, 16 Complete Protease Inhibitor
(Roche), 1% Triton X-100, 0.1% SDS). Two micrograms of the
lysed cell pellets were used for Western blotting.
Immunoprecipitation and Western blotting
Cells were lysed with cold non-denaturing lysis buffer for
20 mins (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 10 mM
EDTA, 0.5% Igepal CA-630 (Sigma), 16 Complete EDTA-free
proteinase inhibitor (Roche)) and pre-cleared by centrifugation at
16,0006g for 15 mins. Two micrograms of primary antibody was
diluted in 500 ml of cold PBS with 0.01% Triton X-100 and mixed
with 15 ml of a 50% protein A-sepharose at 4uC for 1 hour with
gentle rocking. Beads were washed 3 times with PBS and once
with lysis buffer. 5 ml of 10% BSA was added to the beads and
mixed with 600 mg–1 mg of pre-cleared cell lysate in a 500 ml–
1 ml volume at 4uC for 2 hours with gentle rocking. Beads were
washed 3 times with cold lysis buffer and once with PBS.
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and separated on a 10% SDS-PAGE gel. Protein was transferred
to PVDF membrane by wet or semi-dry transfer. Western blotting
was carried out by blocking the membrane for 1 hour in 5% skim
milk followed by a ,16 hour incubation with 1:1000 dilution of
primary antibody. Detection was carried out using HRP-labeled
secondary antibody (1:5000 for 30 mins) and the Amersham ECL
Plus Western Blotting Detection System. Membranes were
exposed to Super RX film (Fujifilm) or scanned using a Storm
860 Phosphorimager (Molecular Dynamics). Densitometric anal-
ysis in the linear range of the scanned image was performed using
IQMac (v1.2) software. Western blots requiring quantitation were
verified using an IRDye-labeled secondary antibody (1:20,000 for
30 mins) and the Odyssey Infrared Imaging System (LI-COR
Biosciences) according to manufacturer’s directions.
Knockdown of TRIM22
Nearly confluent HOS-CD4/CXCR4 cells in 12-well plates
(1 ml volume) were transfected with 1.6 mg of pLKO.1, pLKO.1/
eGFPshRNA or pLKO.1/TRIM22shRNA. Cells were cultured for
16 hours, after which they were washed and treated with
increasing concentrations of human IFNb (PBL Biomedical
Laboratories Cat. #11420-1) for 20 hours. The cells were then
washed and transfected with 0.16 mg of pR9 (encoding full-length
HIV-1). After 16 hours, virus released into the supernatant
(800 ml) or contained within 2 mg of the cell lysate were purified
and analyzed by Western blot as described above.
Decreased expression of TRIM22 mRNA was verified by
Northern blot. Briefly, total RNA was isolated using the RNeasy
RNA isolation kit (Qiagen). Twenty micrograms of RNA was
separated on a 1.2% formaldehyde agarose gel and transferred to
a nitrocellulose membrane. A region in the 39UTR of TRIM22
mRNA from nucleotides 1523 to 1983 (GenBank Accession
#BC035582) was PCR amplified from pCMV-SPORT6/
TRIM22 (Open Biosystems Cat. # MHS1010-7508483) and
random-labeled with aP
32 for use as a probe. Differences in
loading amounts were assessed using a b-actin mRNA probe end-
labeled with cP
32. Membranes were analyzed using a Storm 860
Phosphorimager.
Gag localization
HOS-CD4/CXCR4 cells cultured in 12-well plates on 18mm
coverslips were co-transfected with pTRIM22 and pGag/GFP
(10:1 ratio respectively) for 3 hours, washed and then treated with
100 mg/ml of cycloheximide (Sigma) for 3 hours as described in
[44]. Cells were incubated in fresh media to release the
cycloheximide block and incubated for 48 hours. The coverslips
containing the cells were then washed twice with PBS, fixed for
10 mins in PBS containing 5% formaldehyde and 2% sucrose and
then washed twice more with PBS. Coverslips were mounted onto
glass slides with ,15 ml of Vectashield (Vector Laboratories)
containing 0.5 mg/ml DAPI stain and then sealed with nail polish.
Slides were examined using 406 oil immersion using a Zeiss
fluorescence microscope fitted with an Apotome.
Myristoylation assay
HOS cells ,90% confluent in 6-well plates were co-transfected
with 0.4 mg pGag and 4 mg of pcDNA3.1 or pTRIM22 for
24 hours. Cells were then labeled with 100 mCi/ml of
3H-myristic
acid (Perkin Elmer) for 16 hours. Cells were washed 4 times with
PBS and subjected to immunoprecipitation using p24CA anti-
bodies as described above. Samples were resolved on a 10% SDS-
PAGE gel, impregnated with EN
3HANCE scintillant (Perkin
Elmer), dried and exposed to a phosphorimager screen for 3 days
at room temperature. The screen was analyzed using a Storm 860
Phosphorimager and IQMac (v1.2) software.
Pulse-chase assay
The pulse-chase stability assay for Gag was carried out as
previously described with some modifications [13]. Nearly
confluent 10 cm dishes containing HOS-CD4/CXCR4 cells were
transfected with 30 mg of pcDNA3.1 or pTRIM22 and 3 mgo f
pGag-opt. After 36 hours, cells were washed with PBS and then
incubated in methionine-, cystine- and cysteine-free DMEM (MP
Biomedicals) for 1 hour. Cells were labeled for 45 mins with
50 mCi/ml of [
35S] EasyTag Express Protein Labeling Mix (Perkin
Elmer), washed and incubated in standard DMEM growth media
with 10% heat-inactivated FBS for 0, 1, 2 or 4 hours. Cells were
processed for immunoprecipitation with monoclonal p24 antibod-
ies as described earlier. Precipitated proteins were separated on a
10% SDS-PAGE gel, impregnated with EN3HANCE scintillant
(Perkin Elmer), dried and analyzed by phosphorimager.
Supporting Information
Table S1 Top 52 probe sets affected by interferon beta
treatment of HOS-CD4/CXCR4 cells.
Found at: doi:10.1371/journal.ppat.1000007.s001 (0.02 MB XLS)
Acknowledgments
We thank members of the Bushman and Smiley labs for helpful discussions
and technical assistance. We thank Jason Yao for help with the Gag-
TRIM22 immunoprecipitation and Holly Saffran for generating the
TRIM22 C15A/C18A mutant.
Author Contributions
Conceived and designed the experiments: SDB JRS FDB. Performed the
experiments: SDB. Analyzed the data: SDB JRS FDB. Contributed
reagents/materials/analysis tools: SDB JRS FDB. Wrote the paper: SDB
JRS FDB.
References
1. Sen GC (2001) Viruses and interferons. Annu Rev Microbiol 55: 255–281.
2. Karpov AV (2001) Endogenous and exogenous interferons in HIV-infection.
Eur J Med Res 6: 507–524.
3. Stark GR, Kerr IM, Williams BRG, Silverman RH, Schreiber RD (1998) How
Cells Respond to Interferons. Annu Rev Biochem 67: 227–264.
4. Der SD, Zhou A, Williams BR, Silverman RH (1998) Identification of genes
differentially regulated by interferon alpha, beta, or gamma using oligonucle-
otide arrays. Proc Natl Acad Sci USA 95: 15623–15628.
5. Agy MB, Acker RL, Sherbert CH, Katze MG (1995) Interferon treatment
inhibits virus replication in HIV-1 and SIV-infected CD4+ T-cell lines by
distinct mechanisms: evidence for decreased stability and aberrant processing of
HIV-1 proteins. Virology 214: 379–386.
6. Coccia EM, Krust B, Hovanessian AG (1994) Specific inhibition of viral protein
synthesis in HIV-infected cells in response to interferon treatment. J Biol Chem
269: 23087–23094.
7. Baca-Regen L, Heinzinger N, Stevenson M, Gendelman HE (1994) Alpha
interferon-induced antiretroviral activities: restriction of viral nucleic acid
synthesis and progeny virion production in human immunodeficiency virus
type 1-infected monocytes. J Virol 68: 7559–7565.
8 .H a n s e nB D ,N a r aP L ,M a h e s h w a r iR K ,S i d h uG S ,B e r n b a u mJ G ,
et al. (1992) Loss of infectivity by progeny virus from alpha
interferon-treated human immunodeficiency virus type 1-infected T cells is
associated with defective assembly of envelope gp120. J Virol 66:
7543–7548.
9. Fernie BF, Poli G, Fauci AS (1991) Alpha interferon suppresses virion but not
soluble human immunodeficiency virus antigen production in chronically
infected T-lymphocytic cells. J Virol 65: 3968–3971.
10. Shirazi Y, Pitha PM (1992) Alpha interferon inhibits early stages of the
human immunodeficiency virus type 1 replication cycle. J Virol 66: 1321–
1328.
TRIM22 Inhibits HIV Particle Production
PLoS Pathogens | www.plospathogens.org 9 2008 | Volume 4 | Issue 2 | e100000711. Okumura A, Lu G, Pitha-Rowe I, Pitha PM (2006) Innate antiviral response
targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Proc Natl
Acad Sci U S A 103: 1440–1445.
12. Sokolskaja E, Luban J (2006) Cyclophilin, TRIM5, and innate immunity to
HIV-1. Curr Opin Microbiol 9: 404–408.
13. Sakuma R, Noser JA, Ohmine S, Ikeda Y (2007) Rhesus monkey TRIM5alpha
restricts HIV-1 production through rapid degradation of viral Gag polyproteins.
Nat Med.
14. Nisole S, Stoye JP, Saib A (2005) TRIM family proteins: retroviral restriction
and antiviral defence. Nat Rev Microbiol 3: 799–808.
15. Wolf D, Goff SP (2007) TRIM28 Mediates Primer Binding Site-Targeted
Silencing of Murine Leukemia Virus in Embryonic Cells. Cell 131: 46–57.
16. Saurin AJ, Borden KL, Boddy MN, Freemont PS (1996) Does this have a
familiar RING? Trends Biochem Sci 21: 208–214.
17. Xu L, Yang L, Moitra PK, Hashimoto K, Rallabhandi P, et al. (2003) BTBD1
and BTBD2 colocalize to cytoplasmic bodies with the RBCC/tripartite motif
protein, TRIM5delta. Exp Cell Res 288: 84–93.
18. Trockenbacher A, Suckow V, Foerster J, Winter J, Krauss S, et al. (2001) MID1,
mutated in Opitz syndrome, encodes an ubiquitin ligase that targets phosphatase
2A for degradation. Nat Genet 29: 287–294.
19. Urano T, Saito T, Tsukui T, Fujita M, Hosoi T, et al. (2002) Efp targets 14-3-3
sigma for proteolysis and promotes breast tumour growth. Nature 417: 871–875.
20. Gack MU, Shin YC, Joo CH, Urano T, Liang C, et al. (2007) TRIM25 RING-
finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity.
Nature 446: 916–920.
21. Horn EJ, Albor A, Liu Y, El-Hizawi S, Vanderbeek GE, et al. (2004) RING
protein Trim32 associated with skin carcinogenesis has anti-apoptotic and E3-
ubiquitin ligase properties. Carcinogenesis 25: 157–167.
22. Vichi A, Payne DM, Pacheco-Rodriguez G, Moss J, Vaughan M (2005) E3
ubiquitin ligase activity of the trifunctional ARD1 (ADP-ribosylation factor
domain protein 1). Proc Natl Acad Sci U S A 102: 1945–1950.
23. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, et al. (2001) The
tripartite motif family identifies cell compartments. Embo J 20: 2140–2151.
24. Hilton DJ, Richardson RT, Alexander WS, Viney EM, Willson TA, et al. (1998)
Twenty proteins containing a C-terminal SOCS box form five structural classes.
Proc Natl Acad Sci U S A 95: 114–119.
25. Ponting C, Schultz J, Bork P (1997) SPRY domains in ryanodine receptors
(Ca(2+)-release channels). Trends Biochem Sci 22: 193–194.
26. Tissot C, Mechti N (1995) Molecular cloning of a new interferon-induced factor
that represses human immunodeficiency virus type 1 long terminal repeat
expression. J Biol Chem 270: 14891–14898.
27. Bouazzaoui A, Kreutz M, Eisert V, Dinauer N, Heinzelmann A, et al. (2006)
Stimulated trans-acting factor of 50 kDa (Staf50) inhibits HIV-1 replication in
human monocyte-derived macrophages. Virology 356: 79–94.
28. Bandman O, Coleman RT, Loring JF, Seilhamer JJ, Cocks BG (2002)
Complexity of inflammatory responses in endothelial cells and vascular smooth
muscle cells determined by microarray analysis. Ann N Y Acad Sci 975: 77–90.
29. Obad S, Olofsson T, Mechti N, Gullberg U, Drott K (2007) Expression of the
IFN-inducible p53-target gene TRIM22 is down-regulated during erythroid
differentiation of human bone marrow. Leuk Res.
30. Deng YJ, Huang ZX, Zhou CJ, Wang JW, You Y, et al. (2006) Gene profiling
involved in immature CD4+ T lymphocyte responsible for systemic lupus
erythematosus. Mol Immunol 43: 1497–1507.
31. Zirn B, Hartmann O, Samans B, Krause M, Wittmann S, et al. (2006)
Expression profiling of Wilms tumors reveals new candidate genes for different
clinical parameters. Int J Cancer 118: 1954–1962.
32. Gongora C, Tissot C, Cerdan C, Mechti N (2000) The interferon-inducible
Staf50 gene is downregulated during T cell costimulation by CD2 and CD28.
J Interferon Cytokine Res 20: 955–961.
33. Zhang J, Das SC, Kotalik C, Pattnaik AK, Zhang L (2004) The latent
membrane protein 1 of Epstein-Barr virus establishes an antiviral state via
induction of interferon-stimulated genes. J Biol Chem 279: 46335–46342.
34. Renne R, Barry C, Dittmer D, Compitello N, Brown PO, et al. (2001)
Modulation of cellular and viral gene expression by the latency-associated
nuclear antigen of Kaposi’s sarcoma-associated herpesvirus. J Virol 75: 458–468.
35. Izmailova E, Bertley FM, Huang Q, Makori N, Miller CJ, et al. (2003) HIV-1
Tat reprograms immature dendritic cells to express chemoattractants for
activated T cells and macrophages. Nat Med 9: 191–197.
36. Asaoka K, Ikeda K, Hishinuma T, Horie-Inoue K, Takeda S, et al. (2005) A
retrovirus restriction factor TRIM5alpha is transcriptionally regulated by
interferons. Biochem Biophys Res Commun 338: 1950–1956.
37. Chelbi-Alix MK, Pelicano L, Quignon F, Koken MH, Venturini L, et al. (1995)
Induction of the PML protein by interferons in normal and APL cells. Leukemia
9: 2027–2033.
38. Orimo A, Tominaga N, Yoshimura K, Yamauchi Y, Nomura M, et al. (2000)
Molecular cloning of ring finger protein 21 (RNF21)/interferon-responsive
finger protein (ifp1), which possesses two RING-B box-coiled coil domains in
tandem. Genomics 69: 143–149.
39. Rhodes DA, Ihrke G, Reinicke AT, Malcherek G, Towey M, et al. (2002) The
52 000 MW Ro/SS-A autoantigen in Sjogren’s syndrome/systemic lupus
erythematosus (Ro52) is an interferon-gamma inducible tripartite motif protein
associated with membrane proximal structures. Immunology 106: 246–256.
40. Garoff H, Hewson R, Opstelten DJ (1998) Virus maturation by budding.
Microbiol Mol Biol Rev 62: 1171–1190.
41. Hermida-Matsumoto L, Resh MD (2000) Localization of human immunode-
ficiency virus type 1 Gag and Env at the plasma membrane by confocal imaging.
J Virol 74: 8670–8679.
42. Pornillos O, Higginson DS, Stray KM, Fisher RD, Garrus JE, et al. (2003) HIV
Gag mimics the Tsg101-recruiting activity of the human Hrs protein. J Cell Biol
162: 425–434.
43. Garrus JE, von Schwedler UK, Pornillos OW, Morham SG, Zavitz KH, et al.
(2001) Tsg101 and the vacuolar protein sorting pathway are essential for hiv-1
budding. Cell 107: 55–65.
44. Perlman M, Resh MD (2006) Identification of an intracellular trafficking and
assembly pathway for HIV-1 gag. Traffic 7: 731–745.
45. Furuishi K, Matsuoka H, Takama M, Takahashi I, Misumi S, et al. (1997)
Blockage of N-myristoylation of HIV-1 gag induces the production of impotent
progeny virus. Biochem Biophys Res Commun 237: 504–511.
46. Morikawa Y, Hinata S, Tomoda H, Goto T, Nakai M, et al. (1996) Complete
inhibition of human immunodeficiency virus Gag myristoylation is necessary for
inhibition of particle budding. J Biol Chem 271: 2868–2873.
47. Pal R, Reitz MS Jr, Tschachler E, Gallo RC, Sarngadharan MG, et al. (1990)
Myristoylation of gag proteins of HIV-1 plays an important role in virus
assembly. AIDS Res Hum Retroviruses 6: 721–730.
48. Bryant M, Ratner L (1990) Myristoylation-dependent replication and assembly
of human immunodeficiency virus 1. Proc Natl Acad Sci U S A 87: 523–527.
49. Tashiro A, Shoji S, Kubota Y (1989) Antimyristoylation of the gag proteins in
the human immunodeficiency virus-infected cells with N-myristoyl glycinal
diethylacetal resulted in inhibition of virus production. Biochem Biophys Res
Commun 165: 1145–1154.
50. Hicke L (2001) Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2:
195–201.
51. Kerscher O, Felberbaum R, Hochstrasser M (2006) Modification of proteins by
ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol 22: 159–180.
52. Waterman H, Levkowitz G, Alroy I, Yarden Y (1999) The RING finger of c-Cbl
mediates desensitization of the epidermal growth factor receptor. J Biol Chem
274: 22151–22154.
53. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, et al. (2004) The
cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old
World monkeys. Nature 427: 848–853.
54. Finzi A, Orthwein A, Mercier J, Cohen EA (2007) Productive human
immunodeficiency virus type 1 assembly takes place at the plasma membrane.
J Virol 81: 7476–7490.
55. Welsch S, Keppler OT, Habermann A, Allespach I, Krijnse-Locker J, et al.
(2007) HIV-1 buds predominantly at the plasma membrane of primary human
macrophages. PLoS Pathog 3: e36.
56. Poli G, Orenstein JM, Kinter A, Folks TM, Fauci AS (1989) Interferon-alpha
but not AZT suppresses HIV expression in chronically infected cell lines. Science
244: 575–577.
57. Yasuda Y, Miyake S, Kato S, Kita M, Kishida T, et al. (1990) Interferon-alpha
treatment leads to accumulation of virus particles on the surface of cells
persistently infected with the human immunodeficiency virus type 1. J Acquir
Immune Defic Syndr 3: 1046–1051.
58. Crespi M (1989) The effect of interferon on cells persistently infected with HIV.
Aids 3: 33–36.
59. Smith MS, Thresher RJ, Pagano JS (1991) Inhibition of human immunodefi-
ciency virus type 1 morphogenesis in T cells by alpha interferon. Antimicrob
Agents Chemother 35: 62–67.
60. Dianzani F, Castilletti C, Gentile M, Gelderblom HR, Frezza F, et al. (1998)
Effects of IFN alpha on late stages of HIV-1 replication cycle. Biochimie 80:
745–754.
61. Gendelman HE, Baca LM, Turpin J, Kalter DC, Hansen B, et al. (1990)
Regulation of HIV replication in infected monocytes by IFN-alpha. Mechanism
for viral restriction. Journal of Immunology 145: 2669–2676.
62. Gendelman HE, Baca L, Turpin JA, Kalter DC, Hansen BD, et al. (1990)
Restriction of HIV replication in infected T cells and monocytes by interferon-
alpha. AIDS Res Hum Retroviruses 6: 1045–1049.
63. Sakuma R, Noser JA, Ohmine S, Ikeda Y (2007) Rhesus monkey TRIM5alpha
restricts HIV-1 production through rapid degradation of viral Gag polyproteins.
Nat Med 13: 631–635.
64. Nakasato N, Ikeda K, Urano T, Horie-Inoue K, Takeda S, et al. (2006) A
ubiquitin E3 ligase Efp is up-regulated by interferons and conjugated with
ISG15. Biochem Biophys Res Commun 351: 540–546.
65. Wong JJ, Pung YF, Sze NS, Chin KC (2006) HERC5 is an IFN-induced HECT-
type E3 protein ligase that mediates type I IFN-induced ISGylation of protein
targets. Proc Natl Acad Sci U S A 103: 10735–10740.
66. Zou W, Zhang DE (2006) The interferon-inducible ubiquitin-protein isopeptide
ligase (E3) EFP also functions as an ISG15 E3 ligase. J Biol Chem 281:
3989–3994.
67. Neil SJ, Sandrin V, Sundquist WI, Bieniasz PD (2007) An interferon-alpha-
induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but
is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2: 193–203.
68. Spearman P, Horton R, Ratner L, Kuli-Zade I (1997) Membrane binding of
human immunodeficiency virus type 1 matrix protein in vivo supports a
conformational myristyl switch mechanism. J Virol 71: 6582–6592.
69. Resh MD (2004) A myristoyl switch regulates membrane binding of HIV-1 Gag.
Proc Natl Acad Sci U S A 101: 417–418.
TRIM22 Inhibits HIV Particle Production
PLoS Pathogens | www.plospathogens.org 10 2008 | Volume 4 | Issue 2 | e100000770. Tang C, Loeliger E, Luncsford P, Kinde I, Beckett D, et al. (2004) Entropic
switch regulates myristate exposure in the HIV-1 matrix protein. Proc Natl Acad
Sci U S A 101: 517–522.
71. Wu Z, Alexandratos J, Ericksen B, Lubkowski J, Gallo RC, et al. (2004) Total
chemical synthesis of N-myristoylated HIV-1 matrix protein p17: structural and
mechanistic implications of p17 myristoylation. Proc Natl Acad Sci U S A 101:
11587–11592.
72. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and
regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098–1101.
73. Olsen JC (1998) Gene transfer vectors derived from equine infectious anemia
virus. Gene Ther 5: 1481–1487.
74. Han JY, Cannon PM, Lai KM, Zhao Y, Eiden MV, et al. (1997) Identification
of envelope protein residues required for the expanded host range of 10A1
murine leukemia virus. J Virol 71: 8103–8108.
75. Gao F, Li Y, Decker JM, Peyerl FW, Bibollet-Ruche F, et al. (2003) Codon
usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: in vitro
expression and immune responses in DNA-vaccinated mice. AIDS Res Hum
Retroviruses 19: 817–823.
76. Wehrly K, Chesebro B (1997) p24 antigen capture assay for quantification of
human immunodeficiency virus using readily available inexpensive reagents.
Methods 12: 288–293.
77. Chesebro B, Wehrly K, Nishio J, Perryman S (1992) Macrophage-tropic human
immunodeficiency virus isolates from different patients exhibit unusual V3
envelope sequence homogeneity in comparison with T-cell-tropic isolates:
definition of critical amino acids involved in cell tropism. J Virol 66: 6547–6554.
78. Toohey K, Wehrly K, Nishio J, Perryman S, Chesebro B (1995) Human
immunodeficiency virus envelope V1 and V2 regions influence
replication efficiency in macrophages by affecting virus spread. Virology 213:
70–79.
79. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays
applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:
5116–5121.
80. Follenzi A, Ailes LE, Bakovic S, Gueuna M, Naldini L (2000) Gene transfer by
lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol
sequences. Nat Genetics 25: 217–222.
81. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, et al. (1996) In Vivo Gene
Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector.
Science 272: 263–267.
82. Johnson VA, Byington RE, Kaplan JC (1990) Reverse Transcriptase (RT) Assay.
In: Techniques in HIV research Aldovini A, Walker BD, eds. New York:
Stockton Press. pp 98–102.
TRIM22 Inhibits HIV Particle Production
PLoS Pathogens | www.plospathogens.org 11 2008 | Volume 4 | Issue 2 | e1000007